Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Colorectal cancer is the second most common malignancy worldwide and one-third of these tumors are located in the rectum. The treatment may involve up to three modalities: radiotherapy, chemotherapy, and surgery. For several years, thanks mainly to Brazilian researchers, subgroups of patients have been selected for non-surgical treatment when chemoradiotherapy induces a complete clinical response. These treatment regimens have reached a plateau leading researchers to seek strategies that can increase response rates. Intestinal microbiota studies have shown that an overpopulation of certain ana

Trial Details

NCT ID
NCT06793137
Phase
PHASE2
Sponsor
AC Camargo Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Metronidazole
Locations (sample)
  • São Paulo, São Paulo, Brazil|-23.5475,-46.63611

Key Eligibility Criteria

  • Patients over 18 years old with middle and lower rectal adenocarcinoma, classified as locally advanced or where the tumor´s location necessitates r…
  • Tumors located below the peritoneal reflection, as determined by MRI, will be defined as middle and lower rectum;
  • Patients eligible for rectal amputation will be those with tumor whose distal margin is less than 2,0cm from the pectineal line, as determined by r…
  • Patients with middle rectum cancer candidates for radiotherapy as part of neoadjuvant treatment will be included according to the following criteri…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →